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Background. This preliminary study sought to determine the success of photodynamic therapy (PDT) in reducing lesion size in
an eﬀort to assess the potential application of this treatment approach in a neoadjuvant role. Objectives.T oq u a n t i f yt h ee ﬀects
of PDT on lesion area (mm2) for basal cell and squamous cell carcinomas of the face. Results. Eighteen participants (10 BCC
lesions and 8 SCC lesions of the face) were assessed. Four lesions (all from the BCC group) showed a complete response to PDT.
Of the remaining 14 lesions, 85.7% (n = 12) showed reductions in lesion area, while two lesions showed increase in lesion area.
Proportional reductions for the 12 lesions that did not demonstrate complete response or an increase in area following-PDT were
found to range from 13.2% to 85.1%(BCC) and 6.7% to 89.7%(SCC). Conclusions. PDT as a neoadjuvant treatment mayprovide
asimple,eﬃcient, andviableapproach toreducing thearea ofmalignantlesionsofthefacewith theadvantageof reduced cosmetic
and aesthetic morbidities.
1.Introduction
Current trends in clinical dermatology practice suggest an
increase in the incidence of skin cancers in the region of the
head and neck. This would include lesions of the face, an
area of the body where cosmetic changes as a consequence
of cancer treatment are paramount. Although elimination
of the malignancy is the primary emphasis of treatment, the
residualsideeﬀectsoftreatmentcannotbediscounted.While
surgical excision remains the recommended approach to the
treatment of skin cancers on the face, continued eﬀorts to
minimize the impact of treatment must always be carefully
considered.
Skin cancers of the face not only hold signiﬁcant poten-
tial to call attention to themselves, but also have the problem
that once treatment is completed, the residual eﬀects of that
treatment may continue to pose cosmetic concerns [1]. It is
almost certain that any surgical treatment to the face is likely
to leave at least some degree of cosmetic change visible to
the patient and others. Thus, eﬀorts that seek to reduce the
possibility of large resections may carry with it the potential
for reduced cosmetic morbidities. In this circumstance,
it is not unreasonable to assume that larger lesions will
carry the explicit potential for increased posttreatment
cosmetic changes that pose personal and social restrictions.
Consequently, treatment approaches that create a realistic
opportunity to limit the extent of surgical resection oﬀer a
considerableattraction in the management of skin cancers of
the face. For these reasons, our group has worked toward the
goal of evaluating combined methods for the treatment of
facial lesions, thereby not only optimizing surgical treatment
by reducing the anticipated area of resection, but also doing
so with reduced tissue morbidity.
In an eﬀort to facilitate the ability to meet these multiple
desired objectives, we have undertaken the use of photody-
namic therapy (PDT) as a precursor to surgical intervention.
T h ee m p h a s i so ft h i sa p p r o a c hw a sb o r n ei nh o p et h a t
utilizing PDT prior to planned surgery could reduce the
aesthetic impact of treatment on this important bodily area.
Brieﬂy, PDT is able to exploit the intrinsic cellular haem-
biosynthetic pathway in concert with the principles of pho-
toillumination. By doing so, PDT permits the potential
to selectively target malignant cells of the cutaneous sys-
tem with the advantage of avoiding or reducing collateral2 ISRN Dermatology
treatment impact on nearby regions. One of the potential
advantages of PDT for facial lesions is that should surgery be
required, the area of resection may be more circumscribed
[2]. PDT is not a new method of treatment, but its use in
t h o s ew i t hl e s i o n so ft h ef a c ei sn o te x t e n s i v e[ 3–6]. Based
on information provided in the PDT literature to date, this
treatmentmodalityappearstobepredictableinresponse and
is well tolerated by those who receive it [7], so the inherent
treatment limitations appear to be minimal. This is further
enhanced ifPDT isconsideredin a neoadjuvant role pending
surgery. Although PDT cannot be used in some instances,
most particularly in association with basal cell lesions that
are characterized by substantial vertical growth (>2-3mm
thickness) or in association with cutaneous lesions that are
heavilypigmented [2–6],itspotential utilityforwell-selected
cases of malignant lesions of the face is raised.
These concerns become even more critical when lesions
are large in size, a situation that oﬀers the additional chal-
lenges of minimizing the sacriﬁce of lesion-free tissue and
directly seeking to reduce negative aesthetic changes. When
these concerns are weighed collectively, one can see that
treatment of malignant lesions of the face must balance
multiple concerns with the desire of not only eﬀecting treat-
ment success from the standpoint of eliminating cancer, but
doing so in a manner that explicitly minimizes the resulting
surgical defect. Any eﬀort that can facilitate the potential
for smaller surgical excisions holds signiﬁcant potential to
ally additional morbidities that center around posttreatment
cosmetic defects. Therefore, the question of how eﬀective
PDT is if employed presurgically emerges. That is, could
PDT be used as an initial treatment with the speciﬁc goal of
reducing lesion size so that the potential impact of secondary
surgeryforhistologiccurecouldbeachieved?Forthisreason,
we chose to descriptively assess a group of consecutive
patientswho presented to our clinicwith pathologically con-
ﬁrmed malignant lesions of the face.
2.Methods
This study was conducted following full ethical approval
through our institutional review board (University of West-
ern Ontario Health Sciences Research Ethics Board, Review
number 16430).
2.1. Participants. The patient population reported in this
paper included 18 participants with conﬁrmed, biopsy-
veriﬁed nonmelanoma cutaneous lesions. All potential par-
ticipants were referred to our center, a tertiary care skin
cancer clinic for lesion excision and local reconstruction. Of
this group, 10 participants had lesions conﬁrmed pathologi-
cally to be basal cell carcinoma (BCC), while 8 demonstrated
squamous cell carcinoma (SCC), and all were recruited
sequentially within our center. Potential participants were
excluded if they presented with any lesion directly on the
scalp, or one that encroached on the scalp, or lesions on the
neck; thus, the participants described had lesions solely on
the face. Melanoma was an explicit exclusion criterion, as
were in situ carcinomas.
An additional inclusion criterion, is that all participants
presented with a malignant lesion on the face (BCC or SCC)
judged by one of the authors (C. C. Moore) as not being
amenabletosurgicalexcision duetoits size (inmm2),having
theanticipatedextentofnecessaryresectionwithappropriate
oncologic margins, and/or the anatomical proximity of the
lesion and the anticipated surgical excision to remove the
lesion from aesthetically sensitive areas (e.g., eyes, nose,
and lips). Because of the high potential for cosmetic and
aesthetic morbidity associated with these lesions due to
size and location on the face, they were deemed to be
ideal candidates for participation. Finally, participants were
excluded from consideration if they were unable to self-
administer the photosensitizing agent or if they exhibited
possible sensitivity for PDT (i.e., history of cutaneous pho-
tosensitization, porphyria, hypersensitivity to porphyrins,
and/or photodermatosis) [8–10].
2.2. Procedure. Following a full evaluation by one of the
authors (CCM), each of the 18 participants was instructed
by a clinical nurse in how to apply a topical photosensitizer
(5mg of 10% concentrated 5-aminolevulinic acid powder
mixed with an emulsifying Glaxal Base gel) to the lesion.
After individual instruction and conﬁrmation that the appli-
cation process was fully understood and questions answered,
eachparticipantwasthenaskedtoreturnonapredetermined
date. Participants were asked to self-apply the photosensitiz-
ing agent three hours prior to their scheduled appointment.
The application of the photosensitizer 3 hours prior to the
scheduled appointment maximizes its absorption [11–14].
2.2.1. Measurement of Lesion Area. Upon arrival at the skin
clinic, the residual photosensitizer was ﬁrst wiped from
the lesion, and the lesion was ﬂuoresced, demarcated, and
recorded [15]. Fluorescence was completed using a ﬁltered
lamp that emitted a spectra of photoenergy in wavelengths
that ranged from 320 to 400nm. Under ﬂuorescence, the
entire border of the lesion was identiﬁed directly on the
participant’s skin by using a surgical marking pen for
demarcation. Once demarcation was completed, a clear
acetate ﬁlm was placed over the entire area of the lesion,
and its full border was carefully transcribed. Dimensions of
interest included the full length and width of the lesion cir-
cumscribed under photodynamic photodelineation. Lesion
length was the diameter of the greatest magnitude measured
at a precision of 0.5mm. This procedure provided an
index of lesion size in mm2 that was identiﬁed as the
baseline or pretreatment (PDT) measure. All measures were
obtained with reference to the inner marking of the lesion
border; this process served to reduce potential measurement
artifact associated with the width of the surgical marker.
Subsequently, the entire area of the lesion was calculated
using the formula (length/2) × (width/2) × pi. Measures
of post-PDT lesion were taken again using the identical
acetate ﬁlm demarcation procedure described for the pre-
PDT measure. However, post-PDT measures were generated
independently by two of the authors (C. C. Moore and G.
Jeremic).ISRN Dermatology 3
Table 1: Participant demographics.
BCC SCC
Mean age 81 78
Gender
Female 6 2
Male 4 6
Total number of lesions 10 8
Following this process, the participant then received the
standard PDT. Brieﬂy, this protocol involved a sequence
of two 20-minute light exposures; the light exposure was
completedusing adiodelamp that emitslight in wavelengths
of 633nm ± 10nm range. The two treatment exposures
during this single PDT session were completed with a
one-hour dark interval between exposures. Following the
initial PDT treatment, all participants returned to the clinic
and their lesions were measured again using an identical
procedure to that described for the baseline, pretreatment
measure. This second measure obtained at 4 weeks was
identiﬁed as the posttreatment measure.
2.3. Descriptive Analysis of Data. Data related to lesion area
for all the 18 participants was assessed on an individual
participant basis; however, evaluation of pre- and post-PDT
assessments was considered according to histologic grouping
(BCC and SCC) based on unique history of both types
of lesions (Table 1). Because this project was descriptive in
nature with the objective focused on assessing whether PDT
reduced lesion size, and more speciﬁcally, the proportional
extent of that reduction, parametric statistics were not
used. Again, the primary goal of our assessment sought to
determine ifPDT resulted in changes in lesion area (in mm2)
following a single session of PDT and the associated absolute
and proportional level of reduction if observed following
PDT.
3.Results
3.1. Basal Cell Carcinoma. Pre-PDT lesion area measures
f o rp a r t i c i p a n t si nt h eB C Cg r o u pr a n g e df r o m3 1 . 4 m m 2
to 1727.8mm2 with a mean of 303.3 ± 120.93mm2.O f
the 10 lesions in this group of participants, 4 were found
to respond completely to treatment; upon reassessment at
4 weeks following -PDT under ﬂuorescence, there was no
visible lesion observed. Incontrast to these fourparticipants,
one participant exhibited an increase in the lesion area from
377mm2 before-PDT to 428.8 after-PDT measurement. For
the remaining ﬁve participants with BCC, the post-PDT
measures revealed lesion areas that ranged from 4.7mm2 to
188.5mm2. For those who did not have a complete response
to PDT, a proportional reduction from pre-PDT lesion area
was found to range from 13.2% to 85.1% from baseline
lesion area measures (Figure 2). Visual inspection of the raw
data indicated no apparent trend in the extent of lesion area
decrease based on initial measures (Table 2). Interestingly,
however, the largest BCC lesion (area = 1727.82mm2)
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Figure 1: Pre-PDT (blue) and post-PDT (red) measures of lesion
area (in mm2) for participants with SCC lesions (n = 8).
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Figure 2: Pre-PDT (blue) and post-PDT (red) measures of lesion
area (in mm2) for participants with BCC lesions (n = 10).
ParticipantBCC2hasbeenremovedbecausehispre-PDTlesionwas
>1700mm2, thus, altering the scale of change from the remaining
9 participants in this group; however, this participant did have a
complete response to PDT.
showed a complete response while the smallest (area =
31.4mm2)s h o w e dav e r yg o o d ,y e ti n c o m p l e t e ,r e s p o n s e
(post-PDT measure = 4.7mm2, proportional reduction =
85.1%).
3.2. Squamous Cell Carcinoma. Pre-PDT area measures for
the SCC lesions ranged in size from 80.1mm2 to 552.1mm2
(mean area = 270.7mm2). Post-PDT area measures ranged
from 19.6mm2to 329.9mm2 (mean area = 106.8mm2).
Unlike some of those in the BCC group, of the 8 participants
in this group, none were found to respond completely to
this single PDT treatment; similar to that observed on the
BCC group, one SCC lesion was found to increase following
PDT (from 80.1mm2 to 141.4mm2)( Figure 1). Yet for the
remaining 7 lesions, when pre- and post-PDT measures were
assessed, we found a proportional reduction in lesion area
from baseline measures that ranged from 6.7% to 89.4%.
As with the BCC lesion group, no discernable trend was
identiﬁed in the extent of lesion area reduction following
PDT (Table 1).
4.Discussion
The purpose of this descriptive project is to assess the
potential value of topical PDT as an initial treatment for skin4 ISRN Dermatology
Table 2: Pre-PDT and post-PDT lesion size (in mm2) and the proportional change in lesion area size (listed as a percentage of change from
baseline) for BCC and SCC participant groups.
B C Cg r o u p S C Cg r o u p
Pre-PDT Post-PDT Proportional change Pre-PDT Post-PDT Proportional change
47.1 9.4 20.1 106.0 28.3 73.4
1727.8 0.0 100 353.4 329.9 6.7
377.0 428.8 471.2 148.4 67.7
245.5 188.5 23.1 80.1 141.4
197.9 31.4 84.4 155.5 66.8 57.1
31.4 4.7 85.1 552.1 58.9 89.4
55.0 0.0 100 353.4 55.0 84.5
127.2 0.0 100 94.2 19.6 79.2
149.2 129.6 13.2
75.4 0.0 100
cancersoftheface.Therationaleforseekingthisinformation
was contingent upon the desire to reduce lesion size so that
the potential impact of secondary surgery for histologic cure
might be achieved. For this reason, we chose to descriptively
assess a group of consecutive patients who presented to our
clinic with pathologically conﬁrmed malignant lesions of the
face with the goal of quantifying the area of their lesions
pre- and post-PDT. In seeking to determine the viability of
using PDT as a treatment modality for skin cancers of the
face, we also included a sequential series of patients who
presented to our center and who represented a wide range of
lesions sizes; this included an evaluation of 18 participants,
10 who presented with BCC lesions and 8 with SCC lesions.
If the area of a given lesion could be reduced via PDT,
it was our belief that deﬁnitive treatment in the form of
surgical excision could potentially be less aggressive from
the standpoint of tissue excision [15–17]. Consequently, the
potential cosmetic and aesthetic impact of treatment may be
reduced with improved patient outcomeswithout sacriﬁcing
oncologic principles of treatment.
Data gathered from this preliminary study suggest that
PDT may serve as a valuable treatment modality for
malignant lesions of the face. Based on the data obtained,
it appears that PDT can be of value for both BCC and SCC
facial lesions. While two of the 18 participants included in
the study, one who presented with a BCC and the other
with a SCC, were found to have increased lesion areas at
the time of post-PDT measures, 16 (89%) demonstrated
reductions in lesion area following a single PDT treatment.
This ﬁnding supports the potential application of PDT in
a neoadjuvant role for facial lesions where the concern of
cosmetic and aesthetic morbidity is not insigniﬁcant [18–
21]. Additionally, our data revealed that 4 (25%) of the
16 participants who demonstrated a positive response to
PDT (i.e., a reduction in lesion area) showed a complete
response. All these four cases came from the BCC group
which may indicate a particular histological sensitivity to
PDT. Although this assumption cannot be generalized at
present, these preliminary data provide initial validation of
the utility of PDT as a neoadjuvant therapy for BCC lesions
oftheface.However,furtherstudyisclearlyrequiredinorder
to further substantiate and validate this interpretation.
The desire to reduce the potential negative impact of
surgical resections of malignant lesions of the face carries
considerable value in the context of the patients satisfaction
as a treatment outcome. If surgical intervention can be
performed without loss of oncologic safety, but at the same
timestrivetoreducethesizeofresection,thepersonalimpact
on the patient is likely to be substantial. Facial lesions and
the aesthetic consequences of the treatment of such lesions
carry a social impact that hold potential for great disability.
Although some degree of residual cosmetic defect is almost
always going to be present in treatment of any facial lesion, if
the defect can be reduced to a minimum, multiple outcomes
may be enhanced. As a result, we believe that PDT may
serve a valuable role as neoadjuvant therapy for malignant
lesions of the face. It is clear that surgery remains the gold
standard speciﬁc to treatment of skin cancers of the face, yet
the ability to minimize the posttreatment consequences of
surgery cannot be discounted.
In respect to the present work, several limitations must
be noted. First, we have documented the present data solely
in a descriptive fashion. No comparison was undertaken in
an eﬀort to identify whether the reduction in lesion area
was “statistically signiﬁcant.” Our reason for not performing
such analyses was twofold. First, the sample population
required in order to provide a justiﬁable conﬁrmation of the
eﬀectiveness would have to have been substantial. Given that
the lesion size is likely to be highly variable from person to
person both prior to and following treatment, the ability to
distinguish a signiﬁcant change is fraught with problems. In
this vein, the more critical determination centers on whether
or not a given lesion can be reduced in size and what
extent of proportional reduction in size can be conﬁrmed.
As observed in the present work, 16 of 18 participants were
documented to have reduction in lesion area following PDT
with four exhibiting a complete response. Thus, the second
and perhaps a more important reason for documenting the
absolute and subsequent proportional change in lesion area
as a more valuable index was predicated on the notion thatISRN Dermatology 5
it was always anticipated that surgery would be performed.
PDT was used in an eﬀo r tt or e d u c el e s i o na r e as ot h a t
surgery could be optimized with the least likelihood of facial
disﬁgurement. Therefore, if a lesion area could be reduced,
surgical excision could be less extensive with subsequent
cosmetic value without oncologic risk. It is our impression
thatthepresentdataprovidevaluableinformationindicating
that PDT should be considered as an adjuvant treatment
modality for malignancies of the face. While further research
is required, the present ﬁndings on PDT appear to provide
support for continued use and exploration in the context
of treatment approaches for BCC and SCC lesions of the
face. Consequently, we believe the PDT oﬀers a relatively
simple and cost-eﬀective means as a neoadjuvant modality
forfaciallesionswithassociatedadvantagesinsurgicaleﬀorts
to reduce the cosmetic and aesthetic impact of surgical
intervention.
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